Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
14 08 2021
Historique:
received: 16 07 2021
revised: 10 08 2021
accepted: 11 08 2021
entrez: 26 8 2021
pubmed: 27 8 2021
medline: 28 10 2021
Statut: epublish

Résumé

Medulloblastoma is an aggressive primary brain tumor that is extremely rare in adults; therefore, prospective studies are limited. We reviewed the information of all MB patients treated at the CHUM between 2006 and 2017. We divided our cohort by age and further divided adult patients (53%) in two groups, those diagnosed between 2006-2012 and 2013-2017. In our adult population, median follow up was 26 months and SHH-activated MB comprised 39% of tumors. Adult 5yOS was 80% and first-line therapy led to a 5yPFS of 77%. The absence of radiosensitizing chemotherapy (100% vs. 50%;

Identifiants

pubmed: 34436037
pii: curroncol28040271
doi: 10.3390/curroncol28040271
pmc: PMC8395420
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3104-3114

Références

Strahlenther Onkol. 2007 May;183(5):236-40
pubmed: 17497094
J Neurooncol. 2018 Jan;136(1):95-104
pubmed: 29019042
Nat Rev Cancer. 2012 Dec;12(12):818-34
pubmed: 23175120
Eur J Cancer. 1990 Apr;26(4):464-9
pubmed: 2141512
J Neurooncol. 1997 Nov;35(2):169-76
pubmed: 9266455
J Clin Oncol. 2010 Nov 20;28(33):4961-8
pubmed: 20940197
Neuro Oncol. 2016 Jul;18(7):982-90
pubmed: 27106407
J Egypt Natl Canc Inst. 2008 Jun;20(2):175-86
pubmed: 20029474
J Neurol. 2005 Mar;252(3):291-9
pubmed: 16189725
JAMA. 1998 May 13;279(18):1474-6
pubmed: 9600483
Cancer. 2008 Apr 1;112(7):1568-74
pubmed: 18278809
Pediatr Blood Cancer. 2008 Nov;51(5):603-7
pubmed: 18649371
Neuro Oncol. 2017 Feb 1;19(2):259-269
pubmed: 27540083
Am J Clin Oncol. 2014 Feb;37(1):1-7
pubmed: 23111362
J Neurooncol. 2016 Jun;128(2):235-40
pubmed: 26940908
Crit Rev Oncol Hematol. 2004 May;50(2):121-8
pubmed: 15157661
Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):855-60
pubmed: 12377339
Neurosurgery. 2000 Sep;47(3):623-31; discussion 631-2
pubmed: 10981749
Lancet Oncol. 2019 Dec;20(12):e715-e728
pubmed: 31797797
Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):433-40
pubmed: 17498567
Oncotarget. 2018 Jul 10;9(53):30189-30198
pubmed: 30046397
Acta Neuropathol. 2012 Apr;123(4):473-84
pubmed: 22358457
Cancer. 1994 Oct 15;74(8):2352-60
pubmed: 7922986
Neuro Oncol. 2001 Jan;3(1):29-34
pubmed: 11305414
J Neurooncol. 2009 Oct;95(1):81-85
pubmed: 19396401
J Neurooncol. 2012 Feb;106(3):595-600
pubmed: 21874383
N Engl J Med. 1993 Jun 17;328(24):1725-31
pubmed: 8388548
Radiother Oncol. 2018 Apr;127(1):96-102
pubmed: 29373196
J Clin Oncol. 2006 Sep 1;24(25):4202-8
pubmed: 16943538
Neuro Oncol. 2016 Mar;18(3):408-16
pubmed: 26359208

Auteurs

Maria Camila Quinones (MC)

CHUM Research Centre (CrCHUM), Montreal, QC H2X 0A9, Canada.

Karl Bélanger (K)

CHUM Research Centre (CrCHUM), Department of Hematology and Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.

Émilie Lemieux Blanchard (É)

CHUM Research Centre (CrCHUM), Department of Hematology and Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.

Bernard Lemieux (B)

CHUM Research Centre (CrCHUM), Department of Hematology and Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.

Jean-Paul Bahary (JP)

CHUM Research Centre (CrCHUM), Department of Hematology and Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.

Laura G Masucci (LG)

CHUM Research Centre (CrCHUM), Department of Hematology and Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.

David Roberge (D)

CHUM Research Centre (CrCHUM), Department of Hematology and Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.

Cynthia Menard (C)

CHUM Research Centre (CrCHUM), Department of Hematology and Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.

Carole Lambert (C)

CHUM Research Centre (CrCHUM), Department of Hematology and Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.

France Berthelet (F)

CHUM Research Centre (CrCHUM), Department of Hematology and Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.

Robert Moumdjian (R)

CHUM Research Centre (CrCHUM), Department of Hematology and Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.

Marie Florescu (M)

CHUM Research Centre (CrCHUM), Department of Hematology and Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC H2X 3E4, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH